Ticker Details
Kura Oncology, Inc. Kura Oncology Inc is a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers.
IPO Date:	September 16, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.41 | 3.06%
Avg Daily Range (30 D):	$0.35 | 3.27%
Avg Daily Range (90 D):	$0.30 | 2.98%

Institutional Daily Volume
Avg Daily Volume:	.58M
Avg Daily Volume (30 D):	1.28M
Avg Daily Volume (90 D):	1.38M

Trade Size
Avg Trade Size (Sh.):	91
Avg Trade Size (Sh.) (30 D):	77
Avg Trade Size (Sh.) (90 D):	80

Institutional Trades
Total Institutional Trades:	3,204
Avg Institutional Trade:	$1.85M
Avg Institutional Trade (30 D):	$2.06M
Avg Institutional Trade (90 D):	$2.03M
Avg Institutional Trade Volume:	.13M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.99M
Avg Closing Trade (30 D):	$2.32M
Avg Closing Trade (90 D):	$2.37M
Avg Closing Volume:	142.09K

News

Aug 5, 2026 @ 11:30 AM Kura Oncology to Report Second Quarter Financial R... Source: Na

Apr 24, 2026 @ 12:00 PM Kyowa Kirin and Kura Oncology Initiate Japanese Ph... Source: Na

Apr 17, 2026 @ 10:00 AM Kura Oncology Reports Darlifarnib Plus Cabozantini... Source: Na

Apr 3, 2026 @ 11:30 AM Kura Oncology Reports Inducement Grants Under Nasd... Source: Na

Dec 4, 2025 @ 5:20 PM Blood Cancer Therapeutics Reach Critical Commercia... Source: Prnewswire

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-3.37	$-.77	$-.83
Diluted EPS	$-3.37	$-.77	$-.83
Revenue	$77.23M	$20.87M	$18.27M
Gross Profit		$20.63M	$18M
Net Income / Loss	$-296.78M	$-68.33M	$-73.33M
Operating Income / Loss	$-318.09M	$-73.01M	$-78.82M
Cost of Revenue		$.24M	$.26M
Net Cash Flow	$-11.71M	$31.16M	$-110.02M
PE Ratio